Flacort is the smart choice

Background

In the world of clinical medicine, corticosteroids are often viewed as a “necessary evil.” While they are unparalleled in their ability to suppress inflammation, their side effects—from bone loss and weight gain to growth retardation in children—often limit their long-term utility. However, a comprehensive review published in BMC Pharmacology and Toxicology (2017) by Parente has highlighted Deflazacort (the active in our Flacort) as a revolutionary oxazoline-derivative that is redefining the safety-efficacy balance.

The Evolution of the “Perfect” Steroid

The quest for a corticosteroid with high anti-inflammatory potency but minimal side effects led to the development of Deflazacort. Unlike older steroids like Prednisone and Dexamethasone, Flacort is specifically engineered to spare the patient’s metabolic health.

“Deflazacort is a heterocyclic corticosteroid, an oxazoline-derivative of prednisolone, characterized by high efficacy and a substantial lack of sodium-retaining activity.”

Clinical Proof: Efficacy Without the “Collateral Damage”

The Parente review analyzed several landmark studies across various therapeutic areas, demonstrating that Flacort matches the clinical power of traditional steroids while offering a significantly better safety profile.

The “Bone-Sparing” Profile: A Critical Distinction

For many patients, the fear of steroid-induced osteoporosis is real. The study highlights that in kidney-transplant patients, lumbar spine and whole-body Bone Mineral Density (BMD) were significantly better preserved in the Deflazacort group compared to Prednisone. This makes Flacort the strategic choice for:

• Growing Children: Where linear growth and bone mass are at stake.
• Post-Menopausal Women: Who are already at high risk for bone density loss.
• Chronic Users: Who require long-term inflammatory control.

Metabolic Mastery: Avoiding the “Cushingoid” Trap

Beyond bone health, Flacort excels in metabolic stability. Traditional steroids often lead to:

1. Hyperglycemia: By interfering with carbohydrate metabolism.
2. Dyslipidemia: Increasing LDL cholesterol and triglycerides.
3. Fat Accumulation: Leading to the classic “moon face” or Cushingoid appearance. The evidence shows that Flacort has a lower interference with carbohydrate metabolism and prevents the lipid profile worsening seen with older agents, ensuring the patient’s heart and metabolic health remain protected

Conclusion

The Parente review confirms what we have long known: Flacort (Deflazacort) is not just another steroid. It is a smarter, more refined therapeutic agent that allows practitioners to treat inflammation with confidence, knowing their patients’ skeletal and metabolic futures are secure.For the full dose-conversion table and more clinical data on the Flacort range.

References

1. Parente L. Deflazacort: therapeutic index, clinical efficacy and safety. BMC Pharmacol Toxicol. 2017;18:1.
2. Markham A, Bryson HM. Deflazacort: A review of its pharmacological properties and therapeutic efficacy. Drugs. 1995;50(2):317-33.